Yahoo
NYSE American - Delayed Quote USD

AIM ImmunoTech Inc. (AIM)

0.1681 -0.0022 (-1.29%)
At close: October 16 at 4:00:00 PM EDT
0.1647 -0.0034 (-2.02%)
After hours: October 16 at 7:10:00 PM EDT
Chart Range Bar
Loading chart for AIM
  • Previous Close 0.1703
  • Open 0.1733
  • Bid 0.1680 x 590000
  • Ask 0.1719 x 70000
  • Day's Range 0.1661 - 0.1740
  • 52 Week Range 0.1600 - 2.7934
  • Volume 337,397
  • Avg. Volume 4,704,785
  • Market Cap (intraday) 6.706M
  • Beta (5Y Monthly) 1.27
  • PE Ratio (TTM) --
  • EPS (TTM) -2.9800
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 4.25
  • Zacks Rating Neutral

AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. It is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.

aimimmuno.com

19

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/16/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

AIM
84.66%
S&P 500 (^GSPC)
11.89%

1-Year Return

AIM
93.36%
S&P 500 (^GSPC)
15.54%

3-Year Return

AIM
99.62%
S&P 500 (^GSPC)
75.13%

5-Year Return

AIM
99.91%
S&P 500 (^GSPC)
71.30%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 26k
Earnings -3.79M
Profit Margin -14,569.23%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-4M
-3M
-2M
-1M
0
-18000.0%
-16000.0%
-14000.0%

Analyst Insights

View More

Analyst Price Targets

1.50
4.25 Average
0.1681 Current
7.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/20/2026
Analyst Ascendiant Capital
Rating Action Maintains
Rating Buy
Price Action Lowers
Price Target 9 -> 7

Statistics

View More

Valuation Measures

Annual
As of 9/23/2026
  • Market Cap

    8.23M

  • Enterprise Value

    2.18M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    14.73

  • Price/Book (mrq)

    1.06

  • Enterprise Value/Revenue

    23.00

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -82.58%

  • Return on Equity (ttm)

    -2,382.30%

  • Revenue (ttm)

    95k

  • Net Income Avi to Common (ttm)

    -14.27M

  • Diluted EPS (ttm)

    -2.9800

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    9.96M

  • Total Debt/Equity (mrq)

    50.63%

  • Levered Free Cash Flow (ttm)

    -14.06M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

0.1681 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: